241 related articles for article (PubMed ID: 33950224)
1. JAK1 selective inhibitors for the treatment of spondyloarthropathies.
White JPE; Coates LC
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii39-ii44. PubMed ID: 33950224
[TBL] [Abstract][Full Text] [Related]
2. Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Yates M; Mootoo A; Adas M; Bechman K; Rampes S; Patel V; Qureshi S; Cope AP; Norton S; Galloway JB
Arthritis Rheumatol; 2021 May; 73(5):779-788. PubMed ID: 33174384
[TBL] [Abstract][Full Text] [Related]
3. Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis.
Mysler E; Lizarraga A
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii17-ii23. PubMed ID: 33950225
[TBL] [Abstract][Full Text] [Related]
4. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
Braun J; Kiltz U; Baraliakos X
Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
[TBL] [Abstract][Full Text] [Related]
5. Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis.
Avci AB; Feist E; Burmester GR
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii11-ii16. PubMed ID: 33950228
[TBL] [Abstract][Full Text] [Related]
6. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
Hammitzsch A; Lorenz G; Moog P
Front Immunol; 2020; 11():591176. PubMed ID: 33193430
[TBL] [Abstract][Full Text] [Related]
7. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Nash P; Kerschbaumer A; Dörner T; Dougados M; Fleischmann RM; Geissler K; McInnes I; Pope JE; van der Heijde D; Stoffer-Marx M; Takeuchi T; Trauner M; Winthrop KL; de Wit M; Aletaha D; Baraliakos X; Boehncke WH; Emery P; Isaacs JD; Kremer J; Lee EB; Maksymowych WP; Voshaar M; Tam LS; Tanaka Y; van den Bosch F; Westhovens R; Xavier R; Smolen JS
Ann Rheum Dis; 2021 Jan; 80(1):71-87. PubMed ID: 33158881
[TBL] [Abstract][Full Text] [Related]
8. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
van der Heijde D; Baraliakos X; Gensler LS; Maksymowych WP; Tseluyko V; Nadashkevich O; Abi-Saab W; Tasset C; Meuleners L; Besuyen R; Hendrikx T; Mozaffarian N; Liu K; Greer JM; Deodhar A; Landewé R
Lancet; 2018 Dec; 392(10162):2378-2387. PubMed ID: 30360970
[TBL] [Abstract][Full Text] [Related]
10. Selective Janus kinase inhibitors come of age.
O'Shea JJ; Gadina M
Nat Rev Rheumatol; 2019 Feb; 15(2):74-75. PubMed ID: 30622297
[No Abstract] [Full Text] [Related]
11. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
Keeling S; Maksymowych WP
Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
[TBL] [Abstract][Full Text] [Related]
12. Clinical use of Jak 1 inhibitors for rheumatoid arthritis.
Nash P
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii31-ii38. PubMed ID: 33950231
[TBL] [Abstract][Full Text] [Related]
13. The safety of JAK-1 inhibitors.
Clarke B; Yates M; Adas M; Bechman K; Galloway J
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii24-ii30. PubMed ID: 33950230
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Mease P; Coates LC; Helliwell PS; Stanislavchuk M; Rychlewska-Hanczewska A; Dudek A; Abi-Saab W; Tasset C; Meuleners L; Harrison P; Besuyen R; Van der Aa A; Mozaffarian N; Greer JM; Kunder R; Van den Bosch F; Gladman DD
Lancet; 2018 Dec; 392(10162):2367-2377. PubMed ID: 30360969
[TBL] [Abstract][Full Text] [Related]
15. JAK1: Number one in the family; number one in inflammation?
Spinelli FR; Colbert RA; Gadina M
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii3-ii10. PubMed ID: 33950229
[TBL] [Abstract][Full Text] [Related]
16. JAK1 inhibition and inflammatory bowel disease.
Harris C; Cummings JRF
Rheumatology (Oxford); 2021 May; 60(Supple 2):ii45-ii51. PubMed ID: 33950226
[TBL] [Abstract][Full Text] [Related]
17. Use of upadacitinib in the treatment of psoriatic arthritis.
Ross Y; Magrey M
Immunotherapy; 2021 Dec; 13(18):1549-1554. PubMed ID: 34645316
[TBL] [Abstract][Full Text] [Related]
18. Performance of Janus kinase inhibitors in psoriatic arthritis with axial involvement in indirect comparison with ankylosing spondylitis: a retrospective analysis from pooled data.
Wang L; Ping X; Chen W; Xing W
Clin Rheumatol; 2021 May; 40(5):1725-1737. PubMed ID: 33067773
[TBL] [Abstract][Full Text] [Related]
19. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.
Ferreira S; Guttman-Yassky E; Torres T
Am J Clin Dermatol; 2020 Dec; 21(6):783-798. PubMed ID: 32776305
[TBL] [Abstract][Full Text] [Related]
20. JAK selectivity: more precision less troubles.
Roda G; Dal Buono A; Argollo M; Danese S
Expert Rev Gastroenterol Hepatol; 2020 Sep; 14(9):789-796. PubMed ID: 32520647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
